Key facts
- PAhR Therapeutics’s last known valuation is $25.0M (Jul 2025).
- It has raised $14.0M across 1 recorded rounds; the latest was Seed Round ($14.0M) in Jul 2025.
- Notable investors include RA Capital Management, The University of Tokyo Edge Capital, AN Ventures.
- PAhR Therapeutics has filed 1 Form D with the SEC, most recently Jul 2025 ($4.7M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for PAhR Therapeutics
Funding rounds
1 roundsAbout PAhR Therapeutics
Operator of a clinical-stage biotechnology company intended to develop novel therapies for pulmonary arterial hypertension through innovative molecular mechanisms. The company offers cutting-edge treatments targeting the molecular pathophysiology of PAH, enabling customers to access potentially life-saving therapies that address unmet needs in PAH treatment, offering new hope where conventional options fall short.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2025
- Website
- pahrtx.com/
- Ownership
- Privately Held (backing)
PAhR Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PAhR Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PAhR Therapeutics in its N-PORT filings yet. We sweep new filings monthly.